Correspondence to Dr Jeffrey Weber; Jeffrey.Weber@nyulangone.org We wish to thank Eggermont et al1 for their thoughtful communication regarding our recently published article, ‘Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival’2 The authors appear to suggest that the differing conclusions of that article, that there was no significant association between outcome of relapse-free survival and immune-related toxicity, and their recent work based on the EORTC1325/Keynote-054 study indicating the opposite, was due to the differing definitions of toxicity in the two studies. By being overly selective in the choice of side effects of checkpoint inhibition to include in one’s analysis, one may indeed come to a different conclusion from that of Mandala et al, but we stand by the lack of association between immune-related side effects and relapse-free survival observed in the nivolumab data from Checkmate 238 and feel confident in its clinical relevance. Consulting or Advisory Role: AbbVie, Altor Bioscience, Amgen, AstraZeneca, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Genentech, GlaxoSmithKline, Medivation, Merck, Nektar Therapeutics, Novartis, Pieris Pharmaceuticals, Inc. Roche, SELLAS Life Sciences Group, WindMIL Therapeutics; Research Funding: Astellas Pharma, Bristol Myers Squibb, Genentech, Incyte Corporation, Merck, Novartis, Roche; Travel, Accommodations, and Expenses: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech, GlaxoSmithKline, Merck, Novartis, Pieris Pharmaceuticals, Roche; Honoraria: AbbVie, Altor Bioscience, Amgen, AstraZeneca, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Genentech, GlaxoSmithKline, Medivation, Merck, Nektar Therapeutics, Novartis, Pieris Pharmaceuticals, Inc., Roche, SELLAS Life Sciences Group, WindMIL Therapeutics; Stock/Ownership Interests: Biond; Named on a patent submitted by Moffitt Cancer Center for an ipilimumab biomarker; named on a patent submitted from Biodesix for a PD-1 antibody biomarker.